ターゲットDNA RNAシーケンシングの世界市場

ターゲットDNA RNAシーケンシングの世界市場は2030年までに314億米ドルに達する見込み

2024年に117億米ドルと推定されるターゲットDNA RNAシーケンシングの世界市場は、2024年から2030年にかけてCAGR 17.9%で成長し、2030年には314億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるNGSは、CAGR15.8%を記録し、分析期間終了までに170億米ドルに達すると予測されます。その他の製品セグメントの成長率は、分析期間でCAGR 20.7%と推定されます。

米国市場は32億米ドルと推定、中国はCAGR23.2％で成長予測

米国のターゲットDNA RNAシーケンシング市場は、2024年に32億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに69億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは23.2%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ13.5％と16.0％と予測されています。欧州では、ドイツがCAGR約14.2%で成長すると予測されています。

世界のターゲットDNA RNAシーケンシング市場- 主要動向と促進要因のまとめ

ターゲットDNA RNAシーケンシングが全ゲノムやトランスクリプトームアプローチを凌駕している理由とは？

精密医療とハイスループットゲノミクスの時代において、ターゲットDNAおよびRNAシーケンスは、全ゲノムおよびトランスクリプトームシーケンスに代わる実用的かつ効率的な手法として台頭してきました。関心のある特定のゲノム領域や転写産物のサブセットに焦点を当てることで、この方法は、遺伝的変異、発現プロファイル、分子バイオマーカーを調べるための、費用対効果が高く、スケーラブルで、臨床的に適切な方法を提供します。膨大な量の無関係なデータを生成し、集中的な計算リソースを必要とする全ゲノムシーケンスとは異なり、ターゲットシーケンシングにより、研究者や臨床医は疾患経路に関連する既知の遺伝子、制御エレメント、変異ホットスポットを特定することができます。例えば、腫瘍学では、標的化シーケンスパネルにより、臨床医は、より迅速なターンアラウンドとより優れた解釈可能性で、がん関連遺伝子全体の実用的な変異を同定することができます。感染症研究では、標的RNAシーケンスによって病原体特異的な転写産物の解析が可能になり、菌株同定や薬剤耐性プロファイリングに役立ちます。さらに、遺伝性疾患の診断、薬理ゲノミクス、免疫レパートリーのプロファイリングでは、正確で再現性の高い知見を得るために標的アッセイへの依存度が高まっています。ヘルスケアおよびライフサイエンス業界が臨床的に実用的で時間的制約のない遺伝子データを求める中、標的シーケンス法は研究と臨床の実用性のギャップを埋め、過剰なデータノイズの負担なしに、影響力の大きい生物学的疑問に答えるために必要な深さと特異性を提供しています。

技術革新によってターゲットシーケンシングの効率と精度はどのように向上していますか？

シーケンスケミストリ、プローブデザイン、増幅プロトコル、バイオインフォマティクスの進歩により、ターゲットDNAおよびRNAシーケンスの感度、特異性、スループットが大幅に向上しています。ハイブリッドキャプチャーやアンプリコンベースの濃縮などの技術はより洗練され、低頻度のバリアントや構造的に複雑なゲノム領域を正確にターゲティングできるようになっています。アダプティブサンプリング技術により、ナノポアシーケンスプラットフォームでリアルタイムのターゲット選択が可能になり、無駄なリードが減り、効率が向上しています。マルチプレックスライブラリー調製キットと自動化に適したワークフローにより、納期が短縮され、サンプルの取り扱いエラーが減少し、低インプットキットとFFPE対応キットにより、臨床サンプルや劣化サンプルの有用性が拡大しています。データ解析の面では、統合されたバイオインフォマティクス・パイプラインとAIを搭載したバリアントコーラーが、リードマッピング、変異検出、転写産物の定量化の信頼性を、配列解析が困難な領域でも高めています。クラウドベースのプラットフォームは、共同研究、安全なデータ保存、臨床ラボの合理化された報告を促進しています。さらに、デュアルDNA/RNAパネルの開発により、単一サンプルからゲノムとトランスクリプトームの統合プロファイリングが可能になり、これは特に腫瘍学や免疫プロファイリングのアプリケーションで有用です。リード精度の向上、シーケンサーの高速化、試薬キットの低価格化と相まって、これらの技術革新により、ターゲットシーケンサーは単なる重点的な手法ではなく、精密診断やトランスレーショナルリサーチのための技術的に洗練された、広く展開可能なソリューションになりつつあります。

ターゲットDNA RNAシーケンシングはどこで採用され、どのような使用事例が生まれていますか？

ターゲットDNAおよびRNAシーケンスは、臨床、学術、産業の幅広い場面で採用されており、アプリケーションは従来のゲノム研究の枠を大きく超えています。臨床腫瘍学では、ターゲットシーケンシングパネルは今や固形腫瘍や血液悪性腫瘍のルーチンとなっており、実用的な変異の同定、治療選択の指針、微小残存疾患のモニタリングに役立っています。生殖医療や希少疾患の診断では、標的アッセイによって、定義された遺伝子セットにわたる病原性バリアントの迅速なスクリーニングが可能になり、コストと納期を削減しながら診断収率を向上させることができます。感染症調査では、病原体特異的RNAシーケンスが、新たな変異体、抗菌薬耐性マーカー、治療薬に対する転写反応の迅速な同定に利用されています。免疫学およびワクチン開発分野では、標的T細胞およびB細胞レセプターシーケンスを活用して、免疫レパートリーと応答ダイナミクスを研究しています。ヘルスケア以外では、アグリゲノミクスの研究者がターゲットシーケンシングを使用して植物や家畜の形質を分析し、環境モニタリングではRNAパネルが生態系や工業用バイオリアクター内の微生物活動の追跡に役立っています。医薬品開発パイプラインでは、バイオマーカー探索やコンパニオン診断薬開発のために標的シーケンサーを取り入れるケースが増えています。地域的には、臨床ゲノミクスがより成熟している北米と西欧での導入が堅調である一方、アジア太平洋では研究資金の拡大、ゲノミクスの新興エコシステム、精密医療における政府の取り組みが急速な成長をもたらしています。シーケンサーがよりポータブルになり、データ解析がより身近になったことで、学術機関や診断機関の中小規模のラボも標的メソッドを採用するようになり、市場範囲と使用事例の多様性が拡大しています。

ターゲットDNA RNAシーケンシング世界市場の成長加速の原動力は？

ターゲットDNA RNAシーケンシング市場の成長は、臨床需要、調査の優先順位、コスト効率、急速な技術的成熟の収束によってもたらされています。慢性疾患の世界の増加、がんの発生率、個別化医療への関心により、迅速で実用的な遺伝学的洞察への需要が高まっており、標的シーケンサーはそれを提供するのに適しています。全ゲノムアプローチと比較して、標的化手法はシーケンスコストが大幅に低く、データの複雑さが軽減され、報告までの期間が短縮されるため、特にリソースに制約のある環境において、ルーチン診断によりアクセスしやすくなります。マルチオミクス戦略の統合や、空間およびシングルセルシーケンスへの関心の高まりは、研究者がハイスループットの精度とデータの関連性を組み合わせる方法を模索しているため、さらに採用に拍車をかけています。特に腫瘍学、薬理ゲノミクス、遺伝性疾患において、臨床使用のための標的化NGSパネルが規制当局から承認されたことで、これらのアプローチの有用性が検証され、臨床展開が加速しています。ゲノミクス研究における資金調達の増加は、国家シーケンシングプロジェクトやバイオバンク開発を目的とした政府のイニシアチブと相まって、インフラやサポートエコシステムの幅を広げています。学術機関、バイオテクノロジー企業、診断ラボ間のパートナーシップは、特定の集団や疾患向けに調整された特殊パネルの技術革新と商業化を促進しています。同時に、自動化されたユーザーフレンドリーなNGSプラットフォームと統合された解析ソフトウェアが利用可能になったことで、中規模や分散型のラボのアクセスも民主化されつつあります。分子診断とトランスレーショナルリサーチにおいて、精度、スピード、手頃な価格への要求が高まる中、ターゲットDNA RNAシーケンシングは次世代のゲノム医療を形成する上で、ますます中心的な役割を果たすことになるでしょう。

セグメント

製品（NGS、その他）、ワークフロー（プレシーケンス、シーケンス、データ）、タイプ（DNAベースターゲットシーケンシング、RNAベースターゲットシーケンシング）、用途（ヒト生物医学研究、植物・動物科学、創薬、その他）、最終用途（学術研究、病院・クリニック、製薬・バイオテクノロジー企業、その他）

調査対象企業の例

• Agilent Technologies, Inc.
• Azenta Life Sciences（GENEWIZ）
• BGI Genomics
• Bio-Rad Laboratories, Inc.
• CD Genomics
• Element Biosciences
• F. Hoffmann-La Roche Ltd
• Genomatix Software GmbH
• GeneDx
• HudsonAlpha Institute for Biotechnology
• Illumina, Inc.
• Integrated DNA Technologies, Inc.
• Macrogen, Inc.
• New England Biolabs
• Novogene Corporation
• Nugen Technologies, Inc.
• Oxford Nanopore Technologies plc
• Pacific Biosciences of California, Inc.
• Paragon Genomics
• PerkinElmer, Inc.
• PierianDx
• QIAGEN N.V.

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界別SLMのクエリに従う代わりに、ビデオ記録、ブログ、検索エンジン調査、大量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Targeted DNA RNA Sequencing Market to Reach US$31.4 Billion by 2030

The global market for Targeted DNA RNA Sequencing estimated at US$11.7 Billion in the year 2024, is expected to reach US$31.4 Billion by 2030, growing at a CAGR of 17.9% over the analysis period 2024-2030. NGS, one of the segments analyzed in the report, is expected to record a 15.8% CAGR and reach US$17.0 Billion by the end of the analysis period. Growth in the Other Products segment is estimated at 20.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.2 Billion While China is Forecast to Grow at 23.2% CAGR

The Targeted DNA RNA Sequencing market in the U.S. is estimated at US$3.2 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$6.9 Billion by the year 2030 trailing a CAGR of 23.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 13.5% and 16.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 14.2% CAGR.

Global Targeted DNA RNA Sequencing Market - Key Trends & Drivers Summarized

Why Is Targeted DNA RNA Sequencing Gaining Ground Over Whole Genome and Transcriptome Approaches?

In the era of precision medicine and high-throughput genomics, targeted DNA and RNA sequencing has emerged as a practical and efficient alternative to whole genome and transcriptome sequencing. By focusing on specific genomic regions or transcript subsets of interest, this method offers a highly cost-effective, scalable, and clinically relevant way to interrogate genetic variation, expression profiles, and molecular biomarkers. Unlike whole genome sequencing, which can generate enormous amounts of irrelevant data and require intensive computational resources, targeted sequencing enables researchers and clinicians to zero in on known genes, regulatory elements, or mutation hotspots linked to disease pathways. In oncology, for example, targeted sequencing panels allow clinicians to identify actionable mutations across cancer-relevant genes with faster turnaround and better interpretability. In infectious disease research, targeted RNA sequencing enables pathogen-specific transcript analysis, aiding in strain identification and drug resistance profiling. Additionally, hereditary disease diagnostics, pharmacogenomics, and immune repertoire profiling are increasingly reliant on targeted assays for precise, repeatable insights. As the healthcare and life sciences industries seek clinically actionable, time-sensitive genetic data, targeted sequencing methods are bridging the gap between research and clinical utility, offering the depth and specificity needed to answer high-impact biological questions without the burden of excessive data noise.

How Are Technology Innovations Enhancing the Efficiency and Accuracy of Targeted Sequencing?

Advancements in sequencing chemistry, probe design, amplification protocols, and bioinformatics are driving significant improvements in the sensitivity, specificity, and throughput of targeted DNA and RNA sequencing. Techniques such as hybrid capture and amplicon-based enrichment are becoming more refined, enabling accurate targeting of low-frequency variants and structurally complex genomic regions. Adaptive sampling technologies now allow for real-time target selection on nanopore sequencing platforms, reducing wasted reads and increasing efficiency. Multiplexed library preparation kits and automation-friendly workflows are cutting down turnaround times and reducing sample handling errors, while low-input and FFPE-compatible kits are expanding usability in clinical and degraded samples. On the data analysis front, integrated bioinformatics pipelines and AI-powered variant callers are enhancing the reliability of read mapping, mutation detection, and transcript quantification, even in difficult-to-sequence regions. Cloud-based platforms are facilitating collaborative research, secure data storage, and streamlined reporting for clinical labs. Furthermore, the development of dual DNA/RNA panels is supporting integrated genomic and transcriptomic profiling from a single sample, which is particularly useful in oncology and immune profiling applications. Combined with increasing read accuracy, faster sequencers, and more affordable reagent kits, these innovations are making targeted sequencing not just a focused method, but a technically sophisticated and widely deployable solution for precision diagnostics and translational research.

Where Is Targeted DNA RNA Sequencing Being Adopted, and What Are the Emerging Use Cases?

Targeted DNA and RNA sequencing is being adopted across a wide range of clinical, academic, and industrial settings, with applications extending well beyond traditional genomics research. In clinical oncology, targeted sequencing panels are now routine for solid tumors and hematologic malignancies, helping identify actionable mutations, guide therapy selection, and monitor minimal residual disease. In reproductive health and rare disease diagnostics, targeted assays enable rapid screening for pathogenic variants across defined gene sets, improving diagnostic yield while reducing costs and turnaround times. In infectious disease research, pathogen-specific RNA sequencing is being used for rapid identification of emerging variants, antimicrobial resistance markers, and transcriptional responses to therapeutic agents. The immunology and vaccine development fields are leveraging targeted T-cell and B-cell receptor sequencing to study immune repertoires and response dynamics. Beyond healthcare, agrigenomics researchers use targeted sequencing to analyze plant and livestock traits, while in environmental monitoring, RNA panels help track microbial activity in ecosystems and industrial bioreactors. Drug development pipelines are increasingly incorporating targeted sequencing for biomarker discovery and companion diagnostic development. Geographically, adoption is strong in North America and Western Europe, where clinical genomics is more mature, while Asia-Pacific is witnessing rapid growth driven by expanding research funding, genomics startup ecosystems, and government initiatives in precision medicine. With sequencing instruments becoming more portable and data analysis more accessible, small to mid-sized labs in academia and diagnostics are also embracing targeted methods, expanding market reach and diversity of use cases.

What’s Fueling the Accelerated Growth of the Global Targeted DNA RNA Sequencing Market?

The growth of the targeted DNA RNA sequencing market is being driven by the convergence of clinical demand, research prioritization, cost-efficiency, and rapid technological maturation. The global rise in chronic diseases, cancer incidence, and interest in personalized medicine is increasing demand for quick, actionable genetic insights that targeted sequencing is well-equipped to provide. Compared to whole genome approaches, targeted methods offer significantly lower sequencing costs, reduced data complexity, and faster reporting timelines-making them more accessible for routine diagnostics, especially in resource-constrained settings. The integration of multi-omic strategies and growing interest in spatial and single-cell sequencing are further fueling adoption, as researchers seek ways to combine high-throughput precision with data relevance. Regulatory approvals of targeted NGS panels for clinical use, especially in oncology, pharmacogenomics, and inherited diseases, are validating the utility of these approaches and accelerating clinical deployment. Rising funding in genomics research, coupled with government initiatives aimed at national sequencing projects and biobank development, is broadening the infrastructure and support ecosystem. Partnerships between academic institutions, biotech firms, and diagnostic labs are fostering innovation and commercialization of specialized panels tailored for specific populations or diseases. At the same time, the availability of automated, user-friendly NGS platforms and integrated analysis software is democratizing access for mid-sized and decentralized laboratories. As demand for precision, speed, and affordability grows in molecular diagnostics and translational research, targeted DNA RNA sequencing is positioned to play an increasingly central role in shaping the next generation of genomic medicine.

SCOPE OF STUDY:

The report analyzes the Targeted DNA RNA Sequencing market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (NGS, Others); Workflow (Pre-sequencing, Sequencing, Data); Type (DNA-based Targeted Sequencing, RNA-based Targeted Sequencing); Application (Human Biomedical Research, Plant & Animal Sciences, Drug Discovery, Others); End-Use (Academic Research, Hospitals & Clinics, Pharma & Biotech Companies, Others)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 43 Featured) -

• Agilent Technologies, Inc.
• Azenta Life Sciences (GENEWIZ)
• BGI Genomics
• Bio-Rad Laboratories, Inc.
• CD Genomics
• Element Biosciences
• F. Hoffmann-La Roche Ltd
• Genomatix Software GmbH
• GeneDx
• HudsonAlpha Institute for Biotechnology
• Illumina, Inc.
• Integrated DNA Technologies, Inc.
• Macrogen, Inc.
• New England Biolabs
• Novogene Corporation
• Nugen Technologies, Inc.
• Oxford Nanopore Technologies plc
• Pacific Biosciences of California, Inc.
• Paragon Genomics
• PerkinElmer, Inc.
• PierianDx
• QIAGEN N.V.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • Tariff Impact on Global Supply Chain Patterns
  • Targeted DNA RNA Sequencing - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Growing Demand for Actionable Genetic Insights Throws the Spotlight on Targeted DNA RNA Sequencing in Clinical Diagnostics
  • Rising Adoption of Precision Medicine Approaches Propels Use of Focused Sequencing Panels in Oncology and Rare Disease Detection
  • Increased Interest in Transcriptomic Profiling Strengthens the Business Case for Targeted RNA Sequencing in Gene Expression Analysis
  • Integration of Sequencing into Routine Clinical Workflows Drives Adoption of Rapid and Cost-Effective Targeted Approaches
  • Advancements in Probe Design and Library Preparation Technologies Generate Higher Accuracy and Efficiency in Targeted Assays
  • Expansion of Liquid Biopsy Applications Accelerates Demand for Highly Sensitive Targeted Sequencing in Minimal Residual Disease Monitoring
  • Growing Utility in Infectious Disease and Pathogen Detection Expands the Addressable Market for Targeted Sequencing Platforms
  • Supportive Reimbursement Policies and Regulatory Approvals Spur Clinical Adoption of Targeted Genomic Tests
  • Emergence of Single-Cell and Spatial Genomics Drives Integration of Targeted Approaches in Multi-Omic Workflows
  • Use of AI and Machine Learning in Variant Calling Enhances Interpretation Accuracy and Streamlines Bioinformatics Pipelines
  • Decentralization of Genomic Testing Drives Adoption of Targeted Sequencing in Mid-Sized and Regional Laboratories
  • Rising Demand for Companion Diagnostics in Oncology and Pharmacogenomics Fuels Development of Targeted Gene Panels
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Targeted DNA RNA Sequencing Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Targeted DNA RNA Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Targeted DNA RNA Sequencing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for NGS by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for NGS by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for NGS by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Other Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Other Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Other Products by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Drug Discovery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Drug Discovery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Drug Discovery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Human Biomedical Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Human Biomedical Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Human Biomedical Research by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Plant & Animal Sciences by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Plant & Animal Sciences by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Plant & Animal Sciences by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Academic Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Academic Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Academic Research by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Hospitals & Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Pharma & Biotech Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Pre-sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Pre-sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: World 15-Year Perspective for Pre-sequencing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: World 15-Year Perspective for Sequencing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 41: World Recent Past, Current & Future Analysis for Data by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 42: World Historic Review for Data by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: World 15-Year Perspective for Data by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 44: World Recent Past, Current & Future Analysis for DNA-based Targeted Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 45: World Historic Review for DNA-based Targeted Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: World 15-Year Perspective for DNA-based Targeted Sequencing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 47: World Recent Past, Current & Future Analysis for RNA-based Targeted Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 48: World Historic Review for RNA-based Targeted Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: World 15-Year Perspective for RNA-based Targeted Sequencing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Targeted DNA RNA Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 50: USA Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Product - NGS and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: USA Historic Review for Targeted DNA RNA Sequencing by Product - NGS and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: USA 15-Year Perspective for Targeted DNA RNA Sequencing by Product - Percentage Breakdown of Value Sales for NGS and Other Products for the Years 2015, 2025 & 2030
  • TABLE 53: USA Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: USA Historic Review for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: USA 15-Year Perspective for Targeted DNA RNA Sequencing by Application - Percentage Breakdown of Value Sales for Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences for the Years 2015, 2025 & 2030
  • TABLE 56: USA Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: USA Historic Review for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: USA 15-Year Perspective for Targeted DNA RNA Sequencing by End-Use - Percentage Breakdown of Value Sales for Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 59: USA Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: USA Historic Review for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: USA 15-Year Perspective for Targeted DNA RNA Sequencing by Workflow - Percentage Breakdown of Value Sales for Pre-sequencing, Sequencing and Data for the Years 2015, 2025 & 2030
  • TABLE 62: USA Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: USA Historic Review for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: USA 15-Year Perspective for Targeted DNA RNA Sequencing by Type - Percentage Breakdown of Value Sales for DNA-based Targeted Sequencing and RNA-based Targeted Sequencing for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 65: Canada Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Product - NGS and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Canada Historic Review for Targeted DNA RNA Sequencing by Product - NGS and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: Canada 15-Year Perspective for Targeted DNA RNA Sequencing by Product - Percentage Breakdown of Value Sales for NGS and Other Products for the Years 2015, 2025 & 2030
  • TABLE 68: Canada Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Canada Historic Review for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: Canada 15-Year Perspective for Targeted DNA RNA Sequencing by Application - Percentage Breakdown of Value Sales for Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences for the Years 2015, 2025 & 2030
  • TABLE 71: Canada Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Canada Historic Review for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: Canada 15-Year Perspective for Targeted DNA RNA Sequencing by End-Use - Percentage Breakdown of Value Sales for Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 74: Canada Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Canada Historic Review for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: Canada 15-Year Perspective for Targeted DNA RNA Sequencing by Workflow - Percentage Breakdown of Value Sales for Pre-sequencing, Sequencing and Data for the Years 2015, 2025 & 2030
  • TABLE 77: Canada Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Canada Historic Review for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: Canada 15-Year Perspective for Targeted DNA RNA Sequencing by Type - Percentage Breakdown of Value Sales for DNA-based Targeted Sequencing and RNA-based Targeted Sequencing for the Years 2015, 2025 & 2030
• JAPAN
  • Targeted DNA RNA Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 80: Japan Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Product - NGS and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Japan Historic Review for Targeted DNA RNA Sequencing by Product - NGS and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: Japan 15-Year Perspective for Targeted DNA RNA Sequencing by Product - Percentage Breakdown of Value Sales for NGS and Other Products for the Years 2015, 2025 & 2030
  • TABLE 83: Japan Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Japan Historic Review for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: Japan 15-Year Perspective for Targeted DNA RNA Sequencing by Application - Percentage Breakdown of Value Sales for Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences for the Years 2015, 2025 & 2030
  • TABLE 86: Japan Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Japan Historic Review for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: Japan 15-Year Perspective for Targeted DNA RNA Sequencing by End-Use - Percentage Breakdown of Value Sales for Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 89: Japan Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Japan Historic Review for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: Japan 15-Year Perspective for Targeted DNA RNA Sequencing by Workflow - Percentage Breakdown of Value Sales for Pre-sequencing, Sequencing and Data for the Years 2015, 2025 & 2030
  • TABLE 92: Japan Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Japan Historic Review for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: Japan 15-Year Perspective for Targeted DNA RNA Sequencing by Type - Percentage Breakdown of Value Sales for DNA-based Targeted Sequencing and RNA-based Targeted Sequencing for the Years 2015, 2025 & 2030
• CHINA
  • Targeted DNA RNA Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 95: China Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Product - NGS and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: China Historic Review for Targeted DNA RNA Sequencing by Product - NGS and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: China 15-Year Perspective for Targeted DNA RNA Sequencing by Product - Percentage Breakdown of Value Sales for NGS and Other Products for the Years 2015, 2025 & 2030
  • TABLE 98: China Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: China Historic Review for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: China 15-Year Perspective for Targeted DNA RNA Sequencing by Application - Percentage Breakdown of Value Sales for Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences for the Years 2015, 2025 & 2030
  • TABLE 101: China Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: China Historic Review for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 103: China 15-Year Perspective for Targeted DNA RNA Sequencing by End-Use - Percentage Breakdown of Value Sales for Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 104: China Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: China Historic Review for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 106: China 15-Year Perspective for Targeted DNA RNA Sequencing by Workflow - Percentage Breakdown of Value Sales for Pre-sequencing, Sequencing and Data for the Years 2015, 2025 & 2030
  • TABLE 107: China Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: China Historic Review for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 109: China 15-Year Perspective for Targeted DNA RNA Sequencing by Type - Percentage Breakdown of Value Sales for DNA-based Targeted Sequencing and RNA-based Targeted Sequencing for the Years 2015, 2025 & 2030
• EUROPE
  • Targeted DNA RNA Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 110: Europe Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 111: Europe Historic Review for Targeted DNA RNA Sequencing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 112: Europe 15-Year Perspective for Targeted DNA RNA Sequencing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 113: Europe Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Product - NGS and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Europe Historic Review for Targeted DNA RNA Sequencing by Product - NGS and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 115: Europe 15-Year Perspective for Targeted DNA RNA Sequencing by Product - Percentage Breakdown of Value Sales for NGS and Other Products for the Years 2015, 2025 & 2030
  • TABLE 116: Europe Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Europe Historic Review for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 118: Europe 15-Year Perspective for Targeted DNA RNA Sequencing by Application - Percentage Breakdown of Value Sales for Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences for the Years 2015, 2025 & 2030
  • TABLE 119: Europe Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Europe Historic Review for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 121: Europe 15-Year Perspective for Targeted DNA RNA Sequencing by End-Use - Percentage Breakdown of Value Sales for Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 122: Europe Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Europe Historic Review for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 124: Europe 15-Year Perspective for Targeted DNA RNA Sequencing by Workflow - Percentage Breakdown of Value Sales for Pre-sequencing, Sequencing and Data for the Years 2015, 2025 & 2030
  • TABLE 125: Europe Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Europe Historic Review for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 127: Europe 15-Year Perspective for Targeted DNA RNA Sequencing by Type - Percentage Breakdown of Value Sales for DNA-based Targeted Sequencing and RNA-based Targeted Sequencing for the Years 2015, 2025 & 2030
• FRANCE
  • Targeted DNA RNA Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 128: France Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Product - NGS and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: France Historic Review for Targeted DNA RNA Sequencing by Product - NGS and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 130: France 15-Year Perspective for Targeted DNA RNA Sequencing by Product - Percentage Breakdown of Value Sales for NGS and Other Products for the Years 2015, 2025 & 2030
  • TABLE 131: France Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: France Historic Review for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 133: France 15-Year Perspective for Targeted DNA RNA Sequencing by Application - Percentage Breakdown of Value Sales for Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences for the Years 2015, 2025 & 2030
  • TABLE 134: France Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: France Historic Review for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 136: France 15-Year Perspective for Targeted DNA RNA Sequencing by End-Use - Percentage Breakdown of Value Sales for Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 137: France Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: France Historic Review for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 139: France 15-Year Perspective for Targeted DNA RNA Sequencing by Workflow - Percentage Breakdown of Value Sales for Pre-sequencing, Sequencing and Data for the Years 2015, 2025 & 2030
  • TABLE 140: France Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: France Historic Review for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 142: France 15-Year Perspective for Targeted DNA RNA Sequencing by Type - Percentage Breakdown of Value Sales for DNA-based Targeted Sequencing and RNA-based Targeted Sequencing for the Years 2015, 2025 & 2030
• GERMANY
  • Targeted DNA RNA Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 143: Germany Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Product - NGS and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Germany Historic Review for Targeted DNA RNA Sequencing by Product - NGS and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 145: Germany 15-Year Perspective for Targeted DNA RNA Sequencing by Product - Percentage Breakdown of Value Sales for NGS and Other Products for the Years 2015, 2025 & 2030
  • TABLE 146: Germany Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Germany Historic Review for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 148: Germany 15-Year Perspective for Targeted DNA RNA Sequencing by Application - Percentage Breakdown of Value Sales for Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences for the Years 2015, 2025 & 2030
  • TABLE 149: Germany Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Germany Historic Review for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 151: Germany 15-Year Perspective for Targeted DNA RNA Sequencing by End-Use - Percentage Breakdown of Value Sales for Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 152: Germany Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Germany Historic Review for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 154: Germany 15-Year Perspective for Targeted DNA RNA Sequencing by Workflow - Percentage Breakdown of Value Sales for Pre-sequencing, Sequencing and Data for the Years 2015, 2025 & 2030
  • TABLE 155: Germany Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Germany Historic Review for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 157: Germany 15-Year Perspective for Targeted DNA RNA Sequencing by Type - Percentage Breakdown of Value Sales for DNA-based Targeted Sequencing and RNA-based Targeted Sequencing for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 158: Italy Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Product - NGS and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Italy Historic Review for Targeted DNA RNA Sequencing by Product - NGS and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 160: Italy 15-Year Perspective for Targeted DNA RNA Sequencing by Product - Percentage Breakdown of Value Sales for NGS and Other Products for the Years 2015, 2025 & 2030
  • TABLE 161: Italy Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Italy Historic Review for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 163: Italy 15-Year Perspective for Targeted DNA RNA Sequencing by Application - Percentage Breakdown of Value Sales for Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences for the Years 2015, 2025 & 2030
  • TABLE 164: Italy Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Italy Historic Review for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 166: Italy 15-Year Perspective for Targeted DNA RNA Sequencing by End-Use - Percentage Breakdown of Value Sales for Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 167: Italy Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Italy Historic Review for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 169: Italy 15-Year Perspective for Targeted DNA RNA Sequencing by Workflow - Percentage Breakdown of Value Sales for Pre-sequencing, Sequencing and Data for the Years 2015, 2025 & 2030
  • TABLE 170: Italy Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Italy Historic Review for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 172: Italy 15-Year Perspective for Targeted DNA RNA Sequencing by Type - Percentage Breakdown of Value Sales for DNA-based Targeted Sequencing and RNA-based Targeted Sequencing for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Targeted DNA RNA Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 173: UK Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Product - NGS and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: UK Historic Review for Targeted DNA RNA Sequencing by Product - NGS and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 175: UK 15-Year Perspective for Targeted DNA RNA Sequencing by Product - Percentage Breakdown of Value Sales for NGS and Other Products for the Years 2015, 2025 & 2030
  • TABLE 176: UK Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: UK Historic Review for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 178: UK 15-Year Perspective for Targeted DNA RNA Sequencing by Application - Percentage Breakdown of Value Sales for Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences for the Years 2015, 2025 & 2030
  • TABLE 179: UK Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: UK Historic Review for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 181: UK 15-Year Perspective for Targeted DNA RNA Sequencing by End-Use - Percentage Breakdown of Value Sales for Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 182: UK Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: UK Historic Review for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 184: UK 15-Year Perspective for Targeted DNA RNA Sequencing by Workflow - Percentage Breakdown of Value Sales for Pre-sequencing, Sequencing and Data for the Years 2015, 2025 & 2030
  • TABLE 185: UK Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: UK Historic Review for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 187: UK 15-Year Perspective for Targeted DNA RNA Sequencing by Type - Percentage Breakdown of Value Sales for DNA-based Targeted Sequencing and RNA-based Targeted Sequencing for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 188: Spain Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Product - NGS and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Spain Historic Review for Targeted DNA RNA Sequencing by Product - NGS and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 190: Spain 15-Year Perspective for Targeted DNA RNA Sequencing by Product - Percentage Breakdown of Value Sales for NGS and Other Products for the Years 2015, 2025 & 2030
  • TABLE 191: Spain Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Spain Historic Review for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 193: Spain 15-Year Perspective for Targeted DNA RNA Sequencing by Application - Percentage Breakdown of Value Sales for Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences for the Years 2015, 2025 & 2030
  • TABLE 194: Spain Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Spain Historic Review for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 196: Spain 15-Year Perspective for Targeted DNA RNA Sequencing by End-Use - Percentage Breakdown of Value Sales for Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 197: Spain Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Spain Historic Review for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 199: Spain 15-Year Perspective for Targeted DNA RNA Sequencing by Workflow - Percentage Breakdown of Value Sales for Pre-sequencing, Sequencing and Data for the Years 2015, 2025 & 2030
  • TABLE 200: Spain Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Spain Historic Review for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 202: Spain 15-Year Perspective for Targeted DNA RNA Sequencing by Type - Percentage Breakdown of Value Sales for DNA-based Targeted Sequencing and RNA-based Targeted Sequencing for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 203: Russia Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Product - NGS and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Russia Historic Review for Targeted DNA RNA Sequencing by Product - NGS and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 205: Russia 15-Year Perspective for Targeted DNA RNA Sequencing by Product - Percentage Breakdown of Value Sales for NGS and Other Products for the Years 2015, 2025 & 2030
  • TABLE 206: Russia Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Russia Historic Review for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 208: Russia 15-Year Perspective for Targeted DNA RNA Sequencing by Application - Percentage Breakdown of Value Sales for Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences for the Years 2015, 2025 & 2030
  • TABLE 209: Russia Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Russia Historic Review for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 211: Russia 15-Year Perspective for Targeted DNA RNA Sequencing by End-Use - Percentage Breakdown of Value Sales for Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 212: Russia Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Russia Historic Review for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 214: Russia 15-Year Perspective for Targeted DNA RNA Sequencing by Workflow - Percentage Breakdown of Value Sales for Pre-sequencing, Sequencing and Data for the Years 2015, 2025 & 2030
  • TABLE 215: Russia Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Russia Historic Review for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 217: Russia 15-Year Perspective for Targeted DNA RNA Sequencing by Type - Percentage Breakdown of Value Sales for DNA-based Targeted Sequencing and RNA-based Targeted Sequencing for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 218: Rest of Europe Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Product - NGS and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Rest of Europe Historic Review for Targeted DNA RNA Sequencing by Product - NGS and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 220: Rest of Europe 15-Year Perspective for Targeted DNA RNA Sequencing by Product - Percentage Breakdown of Value Sales for NGS and Other Products for the Years 2015, 2025 & 2030
  • TABLE 221: Rest of Europe Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Rest of Europe Historic Review for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 223: Rest of Europe 15-Year Perspective for Targeted DNA RNA Sequencing by Application - Percentage Breakdown of Value Sales for Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences for the Years 2015, 2025 & 2030
  • TABLE 224: Rest of Europe Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Rest of Europe Historic Review for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 226: Rest of Europe 15-Year Perspective for Targeted DNA RNA Sequencing by End-Use - Percentage Breakdown of Value Sales for Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 227: Rest of Europe Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Rest of Europe Historic Review for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 229: Rest of Europe 15-Year Perspective for Targeted DNA RNA Sequencing by Workflow - Percentage Breakdown of Value Sales for Pre-sequencing, Sequencing and Data for the Years 2015, 2025 & 2030
  • TABLE 230: Rest of Europe Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Rest of Europe Historic Review for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 232: Rest of Europe 15-Year Perspective for Targeted DNA RNA Sequencing by Type - Percentage Breakdown of Value Sales for DNA-based Targeted Sequencing and RNA-based Targeted Sequencing for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Targeted DNA RNA Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 233: Asia-Pacific Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 234: Asia-Pacific Historic Review for Targeted DNA RNA Sequencing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 235: Asia-Pacific 15-Year Perspective for Targeted DNA RNA Sequencing by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 236: Asia-Pacific Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Product - NGS and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Asia-Pacific Historic Review for Targeted DNA RNA Sequencing by Product - NGS and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 238: Asia-Pacific 15-Year Perspective for Targeted DNA RNA Sequencing by Product - Percentage Breakdown of Value Sales for NGS and Other Products for the Years 2015, 2025 & 2030
  • TABLE 239: Asia-Pacific Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Asia-Pacific Historic Review for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 241: Asia-Pacific 15-Year Perspective for Targeted DNA RNA Sequencing by Application - Percentage Breakdown of Value Sales for Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences for the Years 2015, 2025 & 2030
  • TABLE 242: Asia-Pacific Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Asia-Pacific Historic Review for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 244: Asia-Pacific 15-Year Perspective for Targeted DNA RNA Sequencing by End-Use - Percentage Breakdown of Value Sales for Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 245: Asia-Pacific Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Asia-Pacific Historic Review for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 247: Asia-Pacific 15-Year Perspective for Targeted DNA RNA Sequencing by Workflow - Percentage Breakdown of Value Sales for Pre-sequencing, Sequencing and Data for the Years 2015, 2025 & 2030
  • TABLE 248: Asia-Pacific Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Asia-Pacific Historic Review for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 250: Asia-Pacific 15-Year Perspective for Targeted DNA RNA Sequencing by Type - Percentage Breakdown of Value Sales for DNA-based Targeted Sequencing and RNA-based Targeted Sequencing for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Targeted DNA RNA Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 251: Australia Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Product - NGS and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Australia Historic Review for Targeted DNA RNA Sequencing by Product - NGS and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 253: Australia 15-Year Perspective for Targeted DNA RNA Sequencing by Product - Percentage Breakdown of Value Sales for NGS and Other Products for the Years 2015, 2025 & 2030
  • TABLE 254: Australia Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Australia Historic Review for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 256: Australia 15-Year Perspective for Targeted DNA RNA Sequencing by Application - Percentage Breakdown of Value Sales for Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences for the Years 2015, 2025 & 2030
  • TABLE 257: Australia Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Australia Historic Review for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 259: Australia 15-Year Perspective for Targeted DNA RNA Sequencing by End-Use - Percentage Breakdown of Value Sales for Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 260: Australia Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Australia Historic Review for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 262: Australia 15-Year Perspective for Targeted DNA RNA Sequencing by Workflow - Percentage Breakdown of Value Sales for Pre-sequencing, Sequencing and Data for the Years 2015, 2025 & 2030
  • TABLE 263: Australia Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Australia Historic Review for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 265: Australia 15-Year Perspective for Targeted DNA RNA Sequencing by Type - Percentage Breakdown of Value Sales for DNA-based Targeted Sequencing and RNA-based Targeted Sequencing for the Years 2015, 2025 & 2030
• INDIA
  • Targeted DNA RNA Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 266: India Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Product - NGS and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: India Historic Review for Targeted DNA RNA Sequencing by Product - NGS and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 268: India 15-Year Perspective for Targeted DNA RNA Sequencing by Product - Percentage Breakdown of Value Sales for NGS and Other Products for the Years 2015, 2025 & 2030
  • TABLE 269: India Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: India Historic Review for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 271: India 15-Year Perspective for Targeted DNA RNA Sequencing by Application - Percentage Breakdown of Value Sales for Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences for the Years 2015, 2025 & 2030
  • TABLE 272: India Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: India Historic Review for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 274: India 15-Year Perspective for Targeted DNA RNA Sequencing by End-Use - Percentage Breakdown of Value Sales for Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 275: India Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: India Historic Review for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 277: India 15-Year Perspective for Targeted DNA RNA Sequencing by Workflow - Percentage Breakdown of Value Sales for Pre-sequencing, Sequencing and Data for the Years 2015, 2025 & 2030
  • TABLE 278: India Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: India Historic Review for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 280: India 15-Year Perspective for Targeted DNA RNA Sequencing by Type - Percentage Breakdown of Value Sales for DNA-based Targeted Sequencing and RNA-based Targeted Sequencing for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 281: South Korea Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Product - NGS and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: South Korea Historic Review for Targeted DNA RNA Sequencing by Product - NGS and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 283: South Korea 15-Year Perspective for Targeted DNA RNA Sequencing by Product - Percentage Breakdown of Value Sales for NGS and Other Products for the Years 2015, 2025 & 2030
  • TABLE 284: South Korea Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: South Korea Historic Review for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 286: South Korea 15-Year Perspective for Targeted DNA RNA Sequencing by Application - Percentage Breakdown of Value Sales for Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences for the Years 2015, 2025 & 2030
  • TABLE 287: South Korea Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: South Korea Historic Review for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 289: South Korea 15-Year Perspective for Targeted DNA RNA Sequencing by End-Use - Percentage Breakdown of Value Sales for Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 290: South Korea Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: South Korea Historic Review for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 292: South Korea 15-Year Perspective for Targeted DNA RNA Sequencing by Workflow - Percentage Breakdown of Value Sales for Pre-sequencing, Sequencing and Data for the Years 2015, 2025 & 2030
  • TABLE 293: South Korea Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: South Korea Historic Review for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 295: South Korea 15-Year Perspective for Targeted DNA RNA Sequencing by Type - Percentage Breakdown of Value Sales for DNA-based Targeted Sequencing and RNA-based Targeted Sequencing for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 296: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Product - NGS and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Rest of Asia-Pacific Historic Review for Targeted DNA RNA Sequencing by Product - NGS and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 298: Rest of Asia-Pacific 15-Year Perspective for Targeted DNA RNA Sequencing by Product - Percentage Breakdown of Value Sales for NGS and Other Products for the Years 2015, 2025 & 2030
  • TABLE 299: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Rest of Asia-Pacific Historic Review for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 301: Rest of Asia-Pacific 15-Year Perspective for Targeted DNA RNA Sequencing by Application - Percentage Breakdown of Value Sales for Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences for the Years 2015, 2025 & 2030
  • TABLE 302: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Rest of Asia-Pacific Historic Review for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 304: Rest of Asia-Pacific 15-Year Perspective for Targeted DNA RNA Sequencing by End-Use - Percentage Breakdown of Value Sales for Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 305: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Rest of Asia-Pacific Historic Review for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 307: Rest of Asia-Pacific 15-Year Perspective for Targeted DNA RNA Sequencing by Workflow - Percentage Breakdown of Value Sales for Pre-sequencing, Sequencing and Data for the Years 2015, 2025 & 2030
  • TABLE 308: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Rest of Asia-Pacific Historic Review for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 310: Rest of Asia-Pacific 15-Year Perspective for Targeted DNA RNA Sequencing by Type - Percentage Breakdown of Value Sales for DNA-based Targeted Sequencing and RNA-based Targeted Sequencing for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Targeted DNA RNA Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 311: Latin America Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 312: Latin America Historic Review for Targeted DNA RNA Sequencing by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 313: Latin America 15-Year Perspective for Targeted DNA RNA Sequencing by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 314: Latin America Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Product - NGS and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 315: Latin America Historic Review for Targeted DNA RNA Sequencing by Product - NGS and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 316: Latin America 15-Year Perspective for Targeted DNA RNA Sequencing by Product - Percentage Breakdown of Value Sales for NGS and Other Products for the Years 2015, 2025 & 2030
  • TABLE 317: Latin America Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 318: Latin America Historic Review for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 319: Latin America 15-Year Perspective for Targeted DNA RNA Sequencing by Application - Percentage Breakdown of Value Sales for Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences for the Years 2015, 2025 & 2030
  • TABLE 320: Latin America Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 321: Latin America Historic Review for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 322: Latin America 15-Year Perspective for Targeted DNA RNA Sequencing by End-Use - Percentage Breakdown of Value Sales for Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 323: Latin America Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 324: Latin America Historic Review for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 325: Latin America 15-Year Perspective for Targeted DNA RNA Sequencing by Workflow - Percentage Breakdown of Value Sales for Pre-sequencing, Sequencing and Data for the Years 2015, 2025 & 2030
  • TABLE 326: Latin America Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 327: Latin America Historic Review for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 328: Latin America 15-Year Perspective for Targeted DNA RNA Sequencing by Type - Percentage Breakdown of Value Sales for DNA-based Targeted Sequencing and RNA-based Targeted Sequencing for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 329: Argentina Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Product - NGS and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 330: Argentina Historic Review for Targeted DNA RNA Sequencing by Product - NGS and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 331: Argentina 15-Year Perspective for Targeted DNA RNA Sequencing by Product - Percentage Breakdown of Value Sales for NGS and Other Products for the Years 2015, 2025 & 2030
  • TABLE 332: Argentina Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 333: Argentina Historic Review for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 334: Argentina 15-Year Perspective for Targeted DNA RNA Sequencing by Application - Percentage Breakdown of Value Sales for Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences for the Years 2015, 2025 & 2030
  • TABLE 335: Argentina Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 336: Argentina Historic Review for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 337: Argentina 15-Year Perspective for Targeted DNA RNA Sequencing by End-Use - Percentage Breakdown of Value Sales for Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 338: Argentina Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 339: Argentina Historic Review for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 340: Argentina 15-Year Perspective for Targeted DNA RNA Sequencing by Workflow - Percentage Breakdown of Value Sales for Pre-sequencing, Sequencing and Data for the Years 2015, 2025 & 2030
  • TABLE 341: Argentina Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 342: Argentina Historic Review for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 343: Argentina 15-Year Perspective for Targeted DNA RNA Sequencing by Type - Percentage Breakdown of Value Sales for DNA-based Targeted Sequencing and RNA-based Targeted Sequencing for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 344: Brazil Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Product - NGS and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 345: Brazil Historic Review for Targeted DNA RNA Sequencing by Product - NGS and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 346: Brazil 15-Year Perspective for Targeted DNA RNA Sequencing by Product - Percentage Breakdown of Value Sales for NGS and Other Products for the Years 2015, 2025 & 2030
  • TABLE 347: Brazil Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 348: Brazil Historic Review for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 349: Brazil 15-Year Perspective for Targeted DNA RNA Sequencing by Application - Percentage Breakdown of Value Sales for Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences for the Years 2015, 2025 & 2030
  • TABLE 350: Brazil Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 351: Brazil Historic Review for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 352: Brazil 15-Year Perspective for Targeted DNA RNA Sequencing by End-Use - Percentage Breakdown of Value Sales for Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 353: Brazil Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 354: Brazil Historic Review for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 355: Brazil 15-Year Perspective for Targeted DNA RNA Sequencing by Workflow - Percentage Breakdown of Value Sales for Pre-sequencing, Sequencing and Data for the Years 2015, 2025 & 2030
  • TABLE 356: Brazil Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 357: Brazil Historic Review for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 358: Brazil 15-Year Perspective for Targeted DNA RNA Sequencing by Type - Percentage Breakdown of Value Sales for DNA-based Targeted Sequencing and RNA-based Targeted Sequencing for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 359: Mexico Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Product - NGS and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 360: Mexico Historic Review for Targeted DNA RNA Sequencing by Product - NGS and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 361: Mexico 15-Year Perspective for Targeted DNA RNA Sequencing by Product - Percentage Breakdown of Value Sales for NGS and Other Products for the Years 2015, 2025 & 2030
  • TABLE 362: Mexico Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 363: Mexico Historic Review for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 364: Mexico 15-Year Perspective for Targeted DNA RNA Sequencing by Application - Percentage Breakdown of Value Sales for Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences for the Years 2015, 2025 & 2030
  • TABLE 365: Mexico Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 366: Mexico Historic Review for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 367: Mexico 15-Year Perspective for Targeted DNA RNA Sequencing by End-Use - Percentage Breakdown of Value Sales for Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 368: Mexico Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 369: Mexico Historic Review for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 370: Mexico 15-Year Perspective for Targeted DNA RNA Sequencing by Workflow - Percentage Breakdown of Value Sales for Pre-sequencing, Sequencing and Data for the Years 2015, 2025 & 2030
  • TABLE 371: Mexico Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 372: Mexico Historic Review for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 373: Mexico 15-Year Perspective for Targeted DNA RNA Sequencing by Type - Percentage Breakdown of Value Sales for DNA-based Targeted Sequencing and RNA-based Targeted Sequencing for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 374: Rest of Latin America Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Product - NGS and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 375: Rest of Latin America Historic Review for Targeted DNA RNA Sequencing by Product - NGS and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 376: Rest of Latin America 15-Year Perspective for Targeted DNA RNA Sequencing by Product - Percentage Breakdown of Value Sales for NGS and Other Products for the Years 2015, 2025 & 2030
  • TABLE 377: Rest of Latin America Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 378: Rest of Latin America Historic Review for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 379: Rest of Latin America 15-Year Perspective for Targeted DNA RNA Sequencing by Application - Percentage Breakdown of Value Sales for Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences for the Years 2015, 2025 & 2030
  • TABLE 380: Rest of Latin America Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 381: Rest of Latin America Historic Review for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 382: Rest of Latin America 15-Year Perspective for Targeted DNA RNA Sequencing by End-Use - Percentage Breakdown of Value Sales for Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 383: Rest of Latin America Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 384: Rest of Latin America Historic Review for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 385: Rest of Latin America 15-Year Perspective for Targeted DNA RNA Sequencing by Workflow - Percentage Breakdown of Value Sales for Pre-sequencing, Sequencing and Data for the Years 2015, 2025 & 2030
  • TABLE 386: Rest of Latin America Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 387: Rest of Latin America Historic Review for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 388: Rest of Latin America 15-Year Perspective for Targeted DNA RNA Sequencing by Type - Percentage Breakdown of Value Sales for DNA-based Targeted Sequencing and RNA-based Targeted Sequencing for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Targeted DNA RNA Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 389: Middle East Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 390: Middle East Historic Review for Targeted DNA RNA Sequencing by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 391: Middle East 15-Year Perspective for Targeted DNA RNA Sequencing by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 392: Middle East Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Product - NGS and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 393: Middle East Historic Review for Targeted DNA RNA Sequencing by Product - NGS and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 394: Middle East 15-Year Perspective for Targeted DNA RNA Sequencing by Product - Percentage Breakdown of Value Sales for NGS and Other Products for the Years 2015, 2025 & 2030
  • TABLE 395: Middle East Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 396: Middle East Historic Review for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 397: Middle East 15-Year Perspective for Targeted DNA RNA Sequencing by Application - Percentage Breakdown of Value Sales for Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences for the Years 2015, 2025 & 2030
  • TABLE 398: Middle East Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 399: Middle East Historic Review for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 400: Middle East 15-Year Perspective for Targeted DNA RNA Sequencing by End-Use - Percentage Breakdown of Value Sales for Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 401: Middle East Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 402: Middle East Historic Review for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 403: Middle East 15-Year Perspective for Targeted DNA RNA Sequencing by Workflow - Percentage Breakdown of Value Sales for Pre-sequencing, Sequencing and Data for the Years 2015, 2025 & 2030
  • TABLE 404: Middle East Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 405: Middle East Historic Review for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 406: Middle East 15-Year Perspective for Targeted DNA RNA Sequencing by Type - Percentage Breakdown of Value Sales for DNA-based Targeted Sequencing and RNA-based Targeted Sequencing for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 407: Iran Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Product - NGS and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 408: Iran Historic Review for Targeted DNA RNA Sequencing by Product - NGS and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 409: Iran 15-Year Perspective for Targeted DNA RNA Sequencing by Product - Percentage Breakdown of Value Sales for NGS and Other Products for the Years 2015, 2025 & 2030
  • TABLE 410: Iran Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 411: Iran Historic Review for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 412: Iran 15-Year Perspective for Targeted DNA RNA Sequencing by Application - Percentage Breakdown of Value Sales for Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences for the Years 2015, 2025 & 2030
  • TABLE 413: Iran Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 414: Iran Historic Review for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 415: Iran 15-Year Perspective for Targeted DNA RNA Sequencing by End-Use - Percentage Breakdown of Value Sales for Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 416: Iran Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 417: Iran Historic Review for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 418: Iran 15-Year Perspective for Targeted DNA RNA Sequencing by Workflow - Percentage Breakdown of Value Sales for Pre-sequencing, Sequencing and Data for the Years 2015, 2025 & 2030
  • TABLE 419: Iran Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 420: Iran Historic Review for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 421: Iran 15-Year Perspective for Targeted DNA RNA Sequencing by Type - Percentage Breakdown of Value Sales for DNA-based Targeted Sequencing and RNA-based Targeted Sequencing for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 422: Israel Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Product - NGS and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 423: Israel Historic Review for Targeted DNA RNA Sequencing by Product - NGS and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 424: Israel 15-Year Perspective for Targeted DNA RNA Sequencing by Product - Percentage Breakdown of Value Sales for NGS and Other Products for the Years 2015, 2025 & 2030
  • TABLE 425: Israel Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 426: Israel Historic Review for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 427: Israel 15-Year Perspective for Targeted DNA RNA Sequencing by Application - Percentage Breakdown of Value Sales for Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences for the Years 2015, 2025 & 2030
  • TABLE 428: Israel Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 429: Israel Historic Review for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 430: Israel 15-Year Perspective for Targeted DNA RNA Sequencing by End-Use - Percentage Breakdown of Value Sales for Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 431: Israel Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 432: Israel Historic Review for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 433: Israel 15-Year Perspective for Targeted DNA RNA Sequencing by Workflow - Percentage Breakdown of Value Sales for Pre-sequencing, Sequencing and Data for the Years 2015, 2025 & 2030
  • TABLE 434: Israel Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 435: Israel Historic Review for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 436: Israel 15-Year Perspective for Targeted DNA RNA Sequencing by Type - Percentage Breakdown of Value Sales for DNA-based Targeted Sequencing and RNA-based Targeted Sequencing for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 437: Saudi Arabia Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Product - NGS and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 438: Saudi Arabia Historic Review for Targeted DNA RNA Sequencing by Product - NGS and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 439: Saudi Arabia 15-Year Perspective for Targeted DNA RNA Sequencing by Product - Percentage Breakdown of Value Sales for NGS and Other Products for the Years 2015, 2025 & 2030
  • TABLE 440: Saudi Arabia Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 441: Saudi Arabia Historic Review for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 442: Saudi Arabia 15-Year Perspective for Targeted DNA RNA Sequencing by Application - Percentage Breakdown of Value Sales for Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences for the Years 2015, 2025 & 2030
  • TABLE 443: Saudi Arabia Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 444: Saudi Arabia Historic Review for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 445: Saudi Arabia 15-Year Perspective for Targeted DNA RNA Sequencing by End-Use - Percentage Breakdown of Value Sales for Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 446: Saudi Arabia Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 447: Saudi Arabia Historic Review for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 448: Saudi Arabia 15-Year Perspective for Targeted DNA RNA Sequencing by Workflow - Percentage Breakdown of Value Sales for Pre-sequencing, Sequencing and Data for the Years 2015, 2025 & 2030
  • TABLE 449: Saudi Arabia Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 450: Saudi Arabia Historic Review for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 451: Saudi Arabia 15-Year Perspective for Targeted DNA RNA Sequencing by Type - Percentage Breakdown of Value Sales for DNA-based Targeted Sequencing and RNA-based Targeted Sequencing for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 452: UAE Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Product - NGS and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 453: UAE Historic Review for Targeted DNA RNA Sequencing by Product - NGS and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 454: UAE 15-Year Perspective for Targeted DNA RNA Sequencing by Product - Percentage Breakdown of Value Sales for NGS and Other Products for the Years 2015, 2025 & 2030
  • TABLE 455: UAE Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 456: UAE Historic Review for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 457: UAE 15-Year Perspective for Targeted DNA RNA Sequencing by Application - Percentage Breakdown of Value Sales for Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences for the Years 2015, 2025 & 2030
  • TABLE 458: UAE Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 459: UAE Historic Review for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 460: UAE 15-Year Perspective for Targeted DNA RNA Sequencing by End-Use - Percentage Breakdown of Value Sales for Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 461: UAE Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 462: UAE Historic Review for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 463: UAE 15-Year Perspective for Targeted DNA RNA Sequencing by Workflow - Percentage Breakdown of Value Sales for Pre-sequencing, Sequencing and Data for the Years 2015, 2025 & 2030
  • TABLE 464: UAE Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 465: UAE Historic Review for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 466: UAE 15-Year Perspective for Targeted DNA RNA Sequencing by Type - Percentage Breakdown of Value Sales for DNA-based Targeted Sequencing and RNA-based Targeted Sequencing for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 467: Rest of Middle East Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Product - NGS and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 468: Rest of Middle East Historic Review for Targeted DNA RNA Sequencing by Product - NGS and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 469: Rest of Middle East 15-Year Perspective for Targeted DNA RNA Sequencing by Product - Percentage Breakdown of Value Sales for NGS and Other Products for the Years 2015, 2025 & 2030
  • TABLE 470: Rest of Middle East Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 471: Rest of Middle East Historic Review for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 472: Rest of Middle East 15-Year Perspective for Targeted DNA RNA Sequencing by Application - Percentage Breakdown of Value Sales for Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences for the Years 2015, 2025 & 2030
  • TABLE 473: Rest of Middle East Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 474: Rest of Middle East Historic Review for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 475: Rest of Middle East 15-Year Perspective for Targeted DNA RNA Sequencing by End-Use - Percentage Breakdown of Value Sales for Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 476: Rest of Middle East Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 477: Rest of Middle East Historic Review for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 478: Rest of Middle East 15-Year Perspective for Targeted DNA RNA Sequencing by Workflow - Percentage Breakdown of Value Sales for Pre-sequencing, Sequencing and Data for the Years 2015, 2025 & 2030
  • TABLE 479: Rest of Middle East Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 480: Rest of Middle East Historic Review for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 481: Rest of Middle East 15-Year Perspective for Targeted DNA RNA Sequencing by Type - Percentage Breakdown of Value Sales for DNA-based Targeted Sequencing and RNA-based Targeted Sequencing for the Years 2015, 2025 & 2030
• AFRICA
  • Targeted DNA RNA Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 482: Africa Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Product - NGS and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 483: Africa Historic Review for Targeted DNA RNA Sequencing by Product - NGS and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 484: Africa 15-Year Perspective for Targeted DNA RNA Sequencing by Product - Percentage Breakdown of Value Sales for NGS and Other Products for the Years 2015, 2025 & 2030
  • TABLE 485: Africa Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 486: Africa Historic Review for Targeted DNA RNA Sequencing by Application - Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 487: Africa 15-Year Perspective for Targeted DNA RNA Sequencing by Application - Percentage Breakdown of Value Sales for Drug Discovery, Other Applications, Human Biomedical Research and Plant & Animal Sciences for the Years 2015, 2025 & 2030
  • TABLE 488: Africa Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 489: Africa Historic Review for Targeted DNA RNA Sequencing by End-Use - Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 490: Africa 15-Year Perspective for Targeted DNA RNA Sequencing by End-Use - Percentage Breakdown of Value Sales for Academic Research, Hospitals & Clinics, Pharma & Biotech Companies and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 491: Africa Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 492: Africa Historic Review for Targeted DNA RNA Sequencing by Workflow - Pre-sequencing, Sequencing and Data Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 493: Africa 15-Year Perspective for Targeted DNA RNA Sequencing by Workflow - Percentage Breakdown of Value Sales for Pre-sequencing, Sequencing and Data for the Years 2015, 2025 & 2030
  • TABLE 494: Africa Recent Past, Current & Future Analysis for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 495: Africa Historic Review for Targeted DNA RNA Sequencing by Type - DNA-based Targeted Sequencing and RNA-based Targeted Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 496: Africa 15-Year Perspective for Targeted DNA RNA Sequencing by Type - Percentage Breakdown of Value Sales for DNA-based Targeted Sequencing and RNA-based Targeted Sequencing for the Years 2015, 2025 & 2030

IV. COMPETITION